期刊文献+

靶向治疗在胃肠道间质瘤中的应用 被引量:4

Targeted therapy and its application on gastrointestinal stromal tumor
下载PDF
导出
摘要 肿瘤的分子靶向治疗逐渐成为肿瘤治疗的关注焦点,分子靶向药物的出现为肿瘤的治疗带来了新的方向。伊马替尼的应用极大地提高了胃肠道间质瘤的生存率,然而其疗效评价的方法、服药的时间、是否可以中断治疗、耐药后的治疗及靶向治疗与外科治疗的结合仍是目前研究的热点。 Targeted therapy has gradually become the focus in the treatment of tumor, with the emerge of more and more targeted drugs which has brought the treatment of tumor into a new era. Imatinib, the tyrosine kinase inhibitor, is one of the important types of targeted therapy, has become the standard of care in adjuvant therapy of gastrointestinal stromal tumor(GIST) with extraordinary effects. However, the questions are still on debate incluing the optimal way to evaluate treatment results, the treatment duration, whether it can be intermitted or not, second line therapy for imatinibintolerance or -resistance and the combination with surgery.
出处 《中国癌症杂志》 CAS CSCD 北大核心 2009年第6期409-411,共3页 China Oncology
关键词 胃肠间质瘤 伊马替尼 靶向治疗 gastrointestinal stromal tumor imatinib targeted tharapy
  • 相关文献

参考文献1

  • 1S. Bonvalot,H. Eldweny,C. Le Péchoux,D. Vanel,P. Terrier,A. Cavalcanti,C. Robert,N. Lassau,A. Le Cesne. Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era[J] 2006,Annals of Surgical Oncology(12):1596~1603

同被引文献43

  • 1Garcia de Polavieja Carrasco MG, de Juan Ferr6 A, Mayorga Femlndez M. Gastrointestinal stromal tumours at present: an ap- proach to burning questions [ J]. Clin Transl Oncol, 2010, 12 (2) :100 -112.
  • 2Miettinen M, Wang Z, Lasota J. DOG1 antibody in the differen- tial diagnosis of gastrointestinal stromal tumors: a study of 1840 eases[J]. Am J Surg Pathol, 2009,33(9) :1401 - 1408.
  • 3Tam C, Rink L, Merkel E, et al. Insulin-like growth factor 1 re- ceptor is a potential therapeutic target for gastrointestinal stromal tumors[ J]. P Natl Acad Sci USA, 2008, 105 (24) : 8387 - 8392.
  • 4Thomas RK, Baker AC, DeBiasi RM, et al. High-throughput oncogene mutation profiling in human cancer [ J ]. Nat Genet, 2007,39(3 ) :347 - 351.
  • 5Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gas- trointestinal stromal tumors, including unusual subtypes[J]. Am J Surg Pathol, 2009,33 (3) :437 - 446.
  • 6Papaetis GS, Syrigos K. Targeted therapy for gastrointestinal stro- mal tumors : current status and future perspectives [ J ]. Cancer Metast Rev, 2010,29( 1 ) : 151 - 170.
  • 7Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology [ J]. Nat Rev Cancer, 2011,11 (12) :865 - 878.
  • 8Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours [ J ]. Histopathology, 2008,53 ( 3 ) :245 - 266.
  • 9Agaram NP, Laquaglia MP, Ustun B, et al. Molecular character- ization of pediatric gastrointestinal stromal tumors. [ J ]. Clin Cancer Res, 2008,14 ( 10 ) : 3204 - 3215.
  • 10Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer [ J ]. Oncologist, 2008,13(1) :16 -24.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部